Statpedia’s Post

The Global Bronchodilators #autoimmunedisease Market size was valued at USD 23.54 billion in 2023 and is poised #breathe to grow from USD 24.98 billion in 2024 to USD 40.12 billion by 2032, growing at a CAGR of 6.1% in the forecast period (2024-2032). The #disabledlife bronchodilators market encompasses the segment of the pharmaceutical industry that deals with #copdatheat medications used to open up the airways in the lungs, making it easier to breathe.  🌐IMIR Market Research Pvt. Ltd. 📚𝐀𝐜𝐜𝐞𝐬𝐬 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: 👇 https://lnkd.in/dV8-6wtE 📚𝐓𝐨𝐩 𝐌𝐨𝐫𝐞 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐀𝐫𝐞:👇 AdvaCare Pharma USA Almirall Amgis Lifescience Ltd. AstraZeneca Boehringer Ingelheim Cambrex Catalent Pharma Solutions Chiesi Group Cipla GSK Glenmark Pharmaceuticals Hikma Pharmaceuticals Lupin Merck Mundipharma Mylan N.V. Nephron Pharmaceuticals Novartis Orion Corporation Perrigo Company plc Pfizer Prasco RALINGTON PHARMA LLP Siemens Healthcare Pvt. Ltd. GmbH STERIS Healthcare EMEA Ranbaxy Sunovion Pharmaceuticals Teva Pharmaceuticals Thermo Fisher Scientific Vectura Group Zydus Group #ulcerativecolitis #adrenalinsufficiency #jointpain #butyoudontlooksick #fibromyalgia #seronegativearthritis #invisibleillnessawareness #osteoarthritis #noteverydisabilityisvisible #ileostomy #incisionalhernia #spoonielife #ostomate #alpha #antitrypsindeficiency #ibdawareness #pulmonaryfibrosis #ostomyawareness #bursitis #sepsissurvivor #spoonie #pulmonology #fibrowarrior #copdawareness #onsteroids #astma

North America accounted for the largest share of the topical drug delivery market. Download PDF Brochure For More Details@ https://lnkd.in/dFducjMX North America accounted for the largest share the global market, followed by Europe, Asia Pacific, Latin America, and the Middle East & Africa. The large share of North America can be attributed to the rising prevalence of target health conditions, the increasing preference for pain-free drug delivery solutions, the growing prevalence of skin diseases, an increasing number of smokers around the world, rising advancements in transdermal patches, and the high demand for drugs that can be self-administered. Key Players Operating Globally: Glenmark Pharmaceuticals Galderma Johnson & Johnson GSK Bausch Health Companies Inc. Hisamitsu Pharmaceutical Co., Inc. Cipla Bayer Viatris 3M Merck Crescita Therapeutics Novartis Boehringer Ingelheim Pfizer Teva Pharmaceuticals Bristol Myers Squibb Lead Chemicals Purdue Pharma L.P. Lavipharm AbbVie CMP Pharma, Inc. ProSolus, Inc. Rusan Pharma Ltd

Codeine Market Outlook 2024-2030 For Additional Information, Get a Sample Copy>>> https://lnkd.in/dswaUvzu The codeine market refers to the segment of the pharmaceutical industry that focuses on the production, distribution, and sale of codeine, an opioid medication used primarily to treat mild to moderate pain, coughing, and diarrhea. As a controlled substance, codeine is often formulated in combination with other medications like acetaminophen or ibuprofen and is available in both prescription and over-the-counter products in some regions. The market includes pharmaceutical companies, healthcare providers, and regulatory bodies, with demand driven by the need for effective pain management and cough suppression. However, it is also regulated due to the potential for misuse and addiction. #KeyPlayers::: Alcaliber (Spain), AUROBINDO PHARMA LTD (India), Endo Pharmaceuticals (United States), GSK (United Kingdom), Johnson & Johnson (United States), Lannett Company, Inc. (United States), Lupin (India), Mallinckrodt Pharmaceuticals (United States), Noramco™ (United States), Rhodes Pharmaceuticals (United States), Sanofi (France), Sun Pharmaceutical Sdn Bhd (India) #CodeineMarket #Codeine #Pharmaceuticals #Pharmaceuticalindustry #pharmaceuticalnews #htfmi #htf HTF Market Intelligence Consulting Pvt Ltd

📊 CELECOXIB: A Key Player in Pain and Inflammation Management 🌟 A peak of 1,220,000 search volumes in June 2024 Uses ▶️ Celecoxib is primarily used for managing pain and inflammation associated with arthritis, acute pain, and menstrual discomfort. Brand Names ▶️ Celebrex, and generic alternatives by various manufacturers. Manufacturers ▶️ Pfizer, Teva Pharmaceuticals, Aurobindo Pharma, Mylan, and Dr. Reddy's Laboratories. Recent studies have further validated Celecoxib's efficacy in managing chronic pain with a lower gastrointestinal risk compared to traditional NSAIDs, reinforcing its market relevance. As the demand for safe pain relief grows, Celecoxib’s significance continues to rise in the pharmaceutical landscape. 🔗 Connect with me to explore more insights and trends in the pharmaceutical industry! ♻️ Reshare this post to keep receiving the latest updates 😉 #Celecoxib #PainManagement #Pharmaceuticals #MarketTrends #ArthritisCare

𝐀𝐧𝐭𝐢𝐛𝐢𝐨𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐢𝐳𝐞 𝐚𝐧𝐝 𝐒𝐡𝐚𝐫𝐞 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬   𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐑𝐄𝐄 𝐒𝐚𝐦𝐩𝐥𝐞: https://lnkd.in/gw9ANMbh   As we navigate through 2024, the 𝐀𝐧𝐭𝐢𝐛𝐢𝐨𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 continues to be a critical area of focus in global healthcare. Here’s a snapshot of where things stand and where they’re headed: 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰: The global antibiotics market is experiencing significant growth, driven by increasing bacterial infections, rising awareness about antibiotic resistance, and advancements in pharmaceutical research. 𝐆𝐫𝐨𝐰𝐭𝐡 𝐃𝐫𝐢𝐯𝐞𝐫𝐬: 𝐑𝐢𝐬𝐢𝐧𝐠 𝐈𝐧𝐜𝐢𝐝𝐞𝐧𝐜𝐞𝐬 𝐨𝐟 𝐈𝐧𝐟𝐞𝐜𝐭𝐢𝐨𝐧𝐬: The prevalence of infections and chronic diseases is fueling the demand for effective antibiotics. 𝐀𝐧𝐭𝐢𝐛𝐢𝐨𝐭𝐢𝐜 𝐑𝐞𝐬𝐢𝐬𝐭𝐚𝐧𝐜𝐞 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬: Enhanced focus on combating antibiotic resistance is pushing innovation in antibiotic development. 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬: New drug delivery systems and research into novel antibiotics are expanding treatment options. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: Wockhardt Ltd. Shionogi Inc. (U.S.) Abbott Allergan GSK Mylan Novartis Teva Pharmaceuticals 𝐀𝐜𝐜𝐞𝐬𝐬 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/ghwf2WTb The future of the Antibiotics Market is dynamic and full of potential. As we continue to tackle the challenges and seize the opportunities, the focus remains on ensuring effective treatments and combating resistance to safeguard global health. #antibioticsmarket #pharmaceuticals #healthcareinnovation #drugdevelopment #antibioticresistance #marketresearch #markettrends #businessinsights 

Have you ever paid attention to the packaging science of your meds. It's interesting what goes behind it. There's lot of research that goes in deciding on the material, form factor and way of packing a particular med. Follow VARIDOSE for more such insights.

💊Acurx Pharmaceuticals' Ibezapolstat Shows Impressive Results!🌟 Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) compared top-line data from its breakthrough antibiotic, Ibezapolstat, against the current standard-of-care drugs on the market, and the results are highly promising! This could mark a significant advancement in treating bacterial infections. 🔬✨ Click the link for the full video👇🏻👇🏻👇🏻 https://lnkd.in/epRqi-Z9 #acurxpharmaceuticals #wellness #health #healthcare #cure #medicine #pharmacy #science #businessupdate #businessnews #business #news #newtothestreet

The #Antibacterial_Drugs_market_size is estimated to increase by USD 65.3 Billion at a #CAGR of 9.61% by 2030. The report includes historic market data from 2024 to 2030. The Current market value is pegged at USD 52.8 Billion. ❄ ➤ 𝐄𝐧𝐪𝐮𝐢𝐫𝐲 𝐌𝐨𝐫𝐞 ⇒ https://lnkd.in/dqw4tPKV ❄𝐃𝐞𝐟𝐢𝐧𝐢𝐭𝐢𝐨𝐧: The Antibacterial Drugs market refers to the pharmaceutical sector focused on the development, production, and distribution of medications designed to treat bacterial infections. These drugs work by targeting and inhibiting the growth of bacteria, thereby helping the body's immune system to combat and eliminate the infection. They are available in various forms, including oral tablets, capsules, injections, and topical creams or ointments. The Antibacterial Drugs market encompasses both branded and generic medications, with pharmaceutical companies continuously innovating to develop new antibiotics to address emerging resistance patterns and improve treatment outcomes. ❄ ➤ 𝗚𝗿𝗮𝗯 𝐒𝐚𝐦𝐩𝐥𝐞 𝗣𝗗𝗙 𝗙𝗼𝗿 𝗠𝗼𝗿𝗲 𝗗𝗲𝘁𝗮𝗶𝗹𝘀 ⇒ https://lnkd.in/dgh4Yem2 ❄ #Keyplayers: F. Hoffmann-La Roche Ltd, Bayer | Pharmaceuticals, Eli Lilly and Company, GSK, Merck KGaA, Darmstadt, Germany, Novartis, Cipla, Pfizer, Sanofi, Teva Pharmaceuticals, Bristol Myers Squibb, KYORIN Pharmaceutical Co., Ltd., Sun Pharmaceutical Sdn Bhd, Shionogi Inc. (U.S.) ❄ ➤ 𝐂𝐥𝐢𝐜𝐤 𝐡𝐞𝐫𝐞 𝐭𝐨 𝐠𝐞𝐭 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐚𝐭 𝐚 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐞𝐝 𝐩𝐫𝐢𝐜𝐞 ⇒ https://lnkd.in/dVTNspyT ❄ HTF Market Intelligence Consulting Pvt Ltd ❄ The Market Mastermind #Antibacterialdrugs #medicine #pharmaceutical #pharma #antifungaldrugs #medicalproducts

𝗔 𝗖𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝐆𝐮𝐢𝐝𝐞 𝐭𝐨  𝐅𝐢𝐛𝐫𝐨𝐦𝐲𝐚𝐥𝐠𝐢𝐚 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 @ https://lnkd.in/dH__Y8Nj The Fibromyalgia Treatment Market was valued at USD 3.32 billion in 2023 and is projected to reach USD 4.51 billion by 2031, experiencing a compound annual growth rate (CAGR) of 3.9% from 2024 to 2031 The Fibromyalgia Treatment Market is undergoing significant transformation, with its valuation at USD 3.32 billion in 2023 and an anticipated growth to USD 4.51 billion by 2031. This market expansion, driven by a compound annual growth rate (CAGR) of 3.9% from 2024 to 2031, reflects the increasing recognition and diagnosis of fibromyalgia, coupled with advancements in therapeutic options. Emerging treatments, enhanced patient awareness, and a growing emphasis on personalized medicine are key factors propelling this growth. As pharmaceutical companies invest in innovative drug development and holistic management approaches, the market is poised to meet the evolving needs of fibromyalgia patients more effectively. 𝐓𝐡𝐞 𝐌𝐚𝐣𝐨𝐫 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 Amneal Pharmaceuticals, Novartis, Viatris , Sun Pharmaceutical Industries Limited, Abbott, Lupin., Zydus Group, Eli Lilly and Company, Teva Pharmaceuticals, AbbVie, and other players #AmnealPharmaceuticals #Novartis #Viatris #SunPharma #AbbottLaboratories #LupinPharma #ZydusLifesciences #EliLilly #TevaPharma #AbbVie #FibromyalgiaTreatment #FibromyalgiaCare #ChronicPainManagement #FibromyalgiaAwareness #PainRelief #Pharmaceuticals #HealthInnovation #MedicalResearch #FibromyalgiaSupport #HealthcareMarket